PTN News and Press, Palatin Technologies Inc. From 10/23/23

2023-10-23 08:31:36 ET Losers: Revolution Medicines ( RVMD ) -31% . Troika Media Group ( TRKA ) -21% . Li-Cycle Holdings Corp ( LICY ) -21% announces review of the rochester hub project . Mmtec ( MTC ) -18% . Palatin Technologies ( ...

2023-10-23 07:49:36 ET More on Palatin Tech Palatin Technologies, Inc. (PTN) Q4 2023 Earnings Call Transcript Palatin receives notice of non-compliance from NYSE American Seeking Alpha’s Quant Rating on Palatin Tech Historical earnings data for Palatin...

Palatin Announces $5 Million Registered Direct Offering PR Newswire CRANBURY, N.J. , Oct. 23, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based ...

2023-10-20 10:06:59 ET More on Health Care: Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the...

2023-10-19 11:11:53 ET More on Palatin Tech Palatin Technologies Q4 2023 Earnings Call Transcript Palatin receives notice of non-compliance from NYSE American Seeking Alpha’s Quant Rating on Palatin Tech Historical earnings data for Palatin Tech ...

2023-10-19 08:45:29 ET Palm Beach, FL – October 19, 2023 – FinancialNewsMedia.com News Commentary – The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in regulating energ...

Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results PR Newswire 7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed $4.6 million in Gross Product Revenue 11% growth ...

Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients PR Newswire Positive data with Palatin's melanocortin-4 receptor (MC4R) agonist plus glucagon like peptide-1 (G...

Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment PR Newswire Data demonstrates oral PL8177 causes diseased colons to move to a healthier state Provides further support for ongoing oral PL817...

2023-10-13 16:28:52 ET More on Palatin Tech Seeking Alpha’s Quant Rating on Palatin Tech Historical earnings data for Palatin Tech Financial information for Palatin Tech For further details see: Palatin receives notice of non-compliance from NYSE A...